Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has accepted Intellipharmaceutics' abbreviated new drug application (ANDA) for generic version of Lamictal XR (lamotrigine extended-release tablets).
Subscribe to our email newsletter
The generic version of Lamictal XR is an anticonvulsant drug which is indicated for the treatment of epilepsy.
Intellipharmaceutics CEO Isa Odidi said their Hypermatrix technology platform continues to assess its ability to replicate the release profiles of a cross section of drugs and they will continue to seek to exploit the capabilities of this platform to expand their pipeline of products in various stages of development.
The company manufactures generic controlled-release and targeted-release oral solid dosage drugs.